42 results about "Plasma products" patented technology

Methods are provided herein for treating substrate surfaces in preparation for subsequent nucleation-sensitive depositions (e.g., polysilicon or poly-SiGe) and adsorption-driven deposition (e.g. atomic layer deposition or ALD). Prior to depositing, the surface is treated with non-depositing plasma products. The treated surface more readily nucleates polysilicon and poly-SiGe (such as for a gate electrode), or more readily adsorbs ALD reactants (such as for a gate dielectric). The surface treatment provides surface moieties more readily susceptible to a subsequent deposition reaction, or more readily susceptible to further surface treatment prior to deposition. By changing the surface termination of the substrate with a low temperature radical treatment, subsequent deposition is advantageously facilitated without depositing a layer of any appreciable thickness and without significantly affecting the bulk properties of the underlying material. Preferably less than 10 Å of the bulk material incorporates the excited species, which can include fluorine, chlorine and particularly nitrogen excited species.

The present invention provides a method for concentrating a protein, in particular a method for concentrating a plasma product, in particular IgG, using glycine in a (two-stage ultrafiltration/diafiltration approach.

A plasma treated gas permeable material is produced by applying an alternating voltage between spaced electrodes, at least one of which is covered with a dielectric barrier and at least one of which comprises a plurality of discrete electrode segments, to generate plasma microdischarges between the spaced electrodes. A gas permeable material is passed between or adjacent to the spaced electrodes. A gas is moved between the electrode segments into and through the space between the electrodes and through the gas permeable material. The gas flows over plasma generation surfaces of the respective electrode segments and is moved at a rate whereby the gas flow between the spaced electrodes is turbulent and so randomises the plasma microdischarges and disperses plasma products that would otherwise give rise to burning instabilities in the gas permeable material, whereby the randomized plasma microdischarges provide a generally uniform plasma treatment of the gas permeable material. Also disclosed is an apparatus for laying out the process.

The invention belongs to the blood product technology field, and discloses a preparation method for leukocyte-depleted platelet rich plasma. The method comprises the following steps: firstly, anticoagulants and blood are drawn and mixed, and whole blood to be separated is obtained; secondly, first centrifugation is carried out, a centrifugate divided into three layers from bottom to top is obtained, and platelet and plasma components in the upper layer are obtained; thirdly, the obtained upper layer components are centrifuged again, and platelet deposition at the bottom and a plasma supernatant are formed; part of the plasma supernatant is drawn, the platelet deposition is subjected to resuspension by the left plasma supernatant, and leukocyte-depleted platelet rich plasma is prepared. The method achieves elimination of leukocytes and enrichment of platelets at the same time, operation is convenient, consumed time is short, the technical indexes of the prepared plasma product are better than technical indexes of present products with the same kind. Centrifugation for two times in the method can be carried out in two centrifuge tubes respectively, or be carried out in one centrifugal device. The invention provides a centrifugal device used for performing the preparation method.

The invention belongs to the technical field of plasma products, and discloses a plasma sorting system and method. The plasma sorting system is characterized in that plasma bottles are grabbed and moved by a manipulator, reinspection results of current products are acquired by use of an identification unit and a controller, the corresponding plasma bottles are placed in a classified manner according to the acquired results, and qualified products are separated from unqualified products; and a loading line is used for automatic loading, an unloading line is used for automatic unloading, the whole process is completely operated by the manipulator, and the identification process does not need manual participation, so that the phenomenon of sorting mistakes is little. The labor intensity of plasma sorting is reduced, and the sorting working efficiency and the quality of blood products are improved.

The invention discloses a blood plasma product for clinical transfusion and a preparation method thereof. The blood plasma product is prepared from cord blood. The preparation method is as follows: the cord blood in placeta umbilic, which is wasted from a term birth infant, is collected and is centrifuged, and nucleated cells are removed; ABO and Rh blood type detection, blood cell and blood plasma component measurement, pathogenic microorganism immunoassay and germiculture are carried out on the obtained blood plasma without the nucleated cells; and qualified blood plasma is detected, a proper amount of protective agent is added, spin-freeze is carried out at the temperature of minus 35 DEG C for 2 hours, and then freeze-drying is carried out at the temperature of 35 DEG C-37 DEG C within 18-20 hours to obtain the freeze-dried cord blood plasma product. The transfusion comprises common clinical transfusion and transfusion in the aspects of malignant tumor subject to chemo-treatment/radiation treatment and poor hematopoiesis diseases caused by aplastic anemia. The cord blood is a special transfusion resource with important treatment function and also a source of important candidate stem cells.

The invention discloses a method for purifying plasma functional proteins from a Cohn fraction IV. The method comprises the following steps: carrying out pretreatment and removing a filter aid and other proteins in the raw materials; carrying out gradient separation by chromatography and collecting the plasma functional proteins in sequence; carrying out sterilization and freeze-drying. The method is high in protein yield and low in cost, comprises the purification process with the pipeline characteristic, has high degree of automation, is suitable for industrialization and achieves comprehensive utilization of the byproduct in plasma product production.

Plasma-treated gas-permeable material produced by applying an alternating voltage between spaced apart electrodes, at least one of which is coated with a dielectric barrier layer, at least one of which consists of a plurality of separate electrode segments , thereby generating plasma microelectrodes between the separated electrodes. A gas permeable material is passed between or adjacent to the spaced electrodes. Gas moves between the electrode segments into and through the spaces between the electrodes and through the gas permeable material. The gas flows across the plasma-generating surfaces of the corresponding electrode segments at a rate such that the gas flow between the electrodes thus separated is in a turbulent state and causes the plasma micro-emissions to randomize and disperse the plasma products, These products would otherwise cause combustion instabilities in the gas permeable material, so that the randomized plasma microdischarge can provide an overall uniform plasma treatment of the gas permeable material. At the same time, the equipment used for the design process is also disclosed.

A dry etching method comprises: exposing an etching region of a workpiece to a plasma product of a depositive gas, the depositive gas having a CF group in a reaction chamber; exposing the etching region to a plasma product of an etching gas in the reaction chamber; exposing the etching region to a plasma product of the depositive gas in the reaction chamber; and exposing the etching region to a plasma product of the etching gas in the reaction chamber. Alternatively, a dry etching method comprises: exposing an etching region of a workpiece to a plasma product of a depositive gas, the depositive gas containing a fluorocarbon-based gas and at least one of CO (carbon monoxide) gas, hydrogen gas, and CH₄ gas in a reaction chamber; exposing the etching region to a plasma product of an etching gas in the reaction chamber; exposing the etching region to a plasma product of the depositive gas in the reaction chamber; and exposing the etching region to a plasma product of the etching gas in the reaction chamber.

A reflective mask cleaning apparatus according to an embodiment comprises a first supply section configured to supply a first solution containing at least one of an organic solvent and a surfactant to a ruthenium-containing capping layer provided in a reflective mask; and a second supply section configured to supply at least one of a reducing solution and an oxygen-free solution to the capping layer.

A reflective mask cleaning apparatus according to an alternative embodiment comprises a third supply section configured to supply a plasma product produced from a reducing gas to a ruthenium-containing capping layer provided in a reflective mask; and a second supply section configured to supply at least one of a reducing solution and an oxygen-free solution to the capping layer.

The invention relates to an integrated scheme for fractionation and purification of plasma products (human albumin, intravenous immunoglobulin (IVIG), clotting factor VIII and clotting factor IX) by sequential chromatography and virus reduction steps. The therapeutically administrable protein IVIG has purity levels exceeding 98%, aggregates and dimers at less than 0.2%, Fc function of >90% and anti-complementary activity of less than 0.5 CH₅₀ per mg of Ig. The distribution of IgG isomers is comparable to the ranges seen in normal plasma. Human albumin for therapeutic use, purified by this integrated scheme has an electrophoretic purity of close to 100%, with monomers exceeding 98%. The levels of aluminium and pre-kallikrein activator are below the detection limit for the respective tests. The Factor IX preparations have a specific activity of ≧200 IU/mg. The impurity levels of Factor-II, Factor VII, Factor X are at least 10-fold lesser (≦0.5% instead of 5%) and the heparin impurity of ≦0.01 IU (against 0.5 IU limit for this impurity) is 50-fold lesser the specified pharmacopoeial limits.

The purification carried out by an all-chromatography scheme, avoids the use of ethanol precipitation in the entire manufacturing process of the said four plasma products. The invention describes an integrated process for purifying four different proteins from human plasma to high therapeutic grade purity levels, with a potential to purify more therapeutic proteins from a given plasma sample by incorporating additional chromatography steps in the sequence.

The present invention relates to a plasma product or a serum product with an extremely low risk of viral contamination and a method for producing the same. Before treating plasma or serum to be used as a raw material for producing a plasma product or a serum product using a virus removal membrane, leucocytes contaminating the blood are removed. Thus, a plasma product or a serum product with an extremely low risk of viral contamination can be efficiently produced while preventing clogging. Since clogging scarcely arises, it is possible to carry out efficient filtration without applying an elevated pressure as the filtration proceeds.

The invention concerns a method for preparing a plasma product depleted of one or more thrombogenic factors, comprising the combination of at least two steps chosen from among an ethanol fractionation step, a filtration-adsorption step, a precipitation step with caprylic acid and a chromatography step on ion exchange resin.

In an embodiment, a plasma source includes a first electrode, configured for transfer of one or more plasma source gases through first perforations therein; an insulator, disposed in contact with the first electrode about a periphery of the first electrode; and a second electrode, disposed with a periphery of the second electrode against the insulator such that the first and second electrodes and the insulator define a plasma generation cavity. The second electrode is configured for movement of plasma products from the plasma generation cavity therethrough toward a process chamber. A power supply provides electrical power across the first and second electrodes to ignite a plasma with the one or more plasma source gases in the plasma generation cavity to produce the plasma products. One of the first electrode, the second electrode and the insulator includes a port that provides an optical signal from the plasma.

The invention provides a blood coagulation factor type plasma quick-freezing cold storage which comprises a cold storage body and at least one refrigerating unit, each refrigerating unit comprises a cold storage door, quick-freezing flat plates, a fan system, an evaporator and shielding parts, the cold storage door is arranged on the front side of the refrigerating unit, one side of the cold storage door is the shielding part, and the other side of the cold storage door is the external environment. Each shielding part comprises an inner door and a connecting plate. The quick-freezing flat plates are fixed to the supporting frame and are arranged in multiple layers, and a gap is formed between every two adjacent quick-freezing flat plates to form a containing space. The shielding parts are used for sealing the containing spaces corresponding to the quick-freezing flat plates, and the interior of the refrigerating unit is divided into a plurality of independent sealed containing spaces. When the cold storage door is opened to take plasma products, only the corresponding shielding part on a certain layer needs to be opened, leakage of most cold air is avoided, more accurate temperature control is facilitated, temperature fluctuation is reduced, and quick freezing and activity of stored blood coagulation factor plasma are facilitated.